---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036135"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:35:47.468741+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics reports 2023 revenue $113.5M, net loss $85.5M; ETUARY sales up 13%

## Summary
- Full year 2023 revenue of $113.5M, up from $102.3M in 2022; net loss of $85.5M vs net income of $4.3M in 2022.
- ETUARY sales reached $112.1M in 2023, a 13% increase; sales team covers 35,512 hospitals across PRC.
- Cash and cash equivalents $33.5M as of Dec 31, 2023 vs $25.2M end of 2022.
- Phase 3 trial for F351 in CHB-associated liver fibrosis topline data expected by early 2025; U.S. Phase 2a in NASH planned for 2025.
- Appointed Han Ying as CEO in January 2024; completed business combination with GNI in October 2023.

## SEC filing metadata
- accession: 0000950170-24-036135
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000095017024036135/0000950170-24-036135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000095017024036135/gyre-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036135
- JSON: https://secwatch.observer/filing/0000950170-24-036135.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036135.txt

## Key facts
- Earnings Releases
  GYRE THERAPEUTICS, INC. reported year ended December 31, 2023 results: revenue $112.1 million.
  - Period: year ended December 31, 2023
  - Revenue: $112.1 million
  - Result: reported results
  source text: inflammation modulators. ETUARY became commercially available in the PRC in 2011 and has been included in the National Reimbursement Drug List since 2017. • Generated sales of $112.1 million in 2023. For the year ended December 31, 2023, Gyre Pharmaceuticals generated $112.1 million in sales of ETUARY, representing an increase of 13% from the previous year. As of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000095017024036135/0000950170-24-036135-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.